CJC-1295 no DAC
Purity: 99.368%
CJCNODAC-10-601
12.87 mg
$115.00
CJC-1295 no DAC is a modified GHRH analog used in research on pulsatile growth hormone release and pituitary signaling.
Ships by
Calculating...
Disclaimer
For Research Use Only. Not for human consumption or therapeutic treatment.
About CJC-1295 no DAC
CJC-1295 without DAC is a tetrasubstituted GHRH analog designed for enhanced receptor affinity and predictable pulsatile GH release. Unlike the DAC version, this form has a shorter half-life and is therefore used in models that require dynamic GH pulse frequency rather than sustained elevation. Researchers frequently explore its impact on IGF-1 regulation, pituitary responsiveness, and hypothalamic-pituitary communication.
Product Specifications
CJC-1295 (No DAC) Lyophilized Powder in 3ml vial
Application
Growth hormone–releasing hormone (GHRH) and endocrine-signaling research
Appearance
Solid, white powder in 3mL glass ampule
Chemical Formula
C165H271N47O46
CAS number
863288-34-0
Molecular Weight
~3367.9 g/mol
FAQs
What is CJC-1295 no DAC?
CJC-1295 no DAC is a synthetic analog of growth hormone-releasing hormone consisting of 29 amino acids, corresponding to the first 29 residues of endogenous GHRH with four amino acid substitutions at positions 2, 8, 15, and 27. These substitutions improve metabolic stability and resistance to enzymatic degradation by dipeptidyl peptidase-IV. The designation 'no DAC' indicates the absence of the Drug Affinity Complex, a maleimidopropionic acid conjugate used in the DAC variant to extend half-life through albumin binding.
How does CJC-1295 no DAC differ from the DAC version?
The DAC variant includes a maleimidopropionic acid linker that covalently binds to serum albumin after injection, extending the peptide's circulating half-life to approximately 8 days. CJC-1295 without DAC has a shorter half-life of approximately 30 minutes, producing a more pulsatile growth hormone release pattern that more closely approximates the natural secretory dynamics of endogenous GHRH. Researchers select between the two forms based on whether sustained or pulsatile growth hormone elevation is the desired experimental variable.
What receptor does CJC-1295 no DAC activate?
CJC-1295 no DAC binds to the growth hormone-releasing hormone receptor on somatotroph cells in the anterior pituitary gland. This receptor is a G-protein-coupled receptor that activates adenylyl cyclase, increases intracellular cyclic AMP, and triggers growth hormone synthesis and secretion. Unlike GHRP-6 and ipamorelin, which act through the ghrelin receptor (GHS-R1a), CJC-1295 no DAC operates through the GHRH receptor pathway exclusively.
Is CJC-1295 no DAC studied in combination with other peptides?
CJC-1295 no DAC is frequently studied in combination with growth hormone secretagogues like ipamorelin or GHRP-6 because the two classes of peptides act through different receptors. Published research demonstrates synergistic effects on growth hormone release when GHRH analogs and ghrelin receptor agonists are co-administered, producing a greater amplitude of growth hormone pulses than either compound administered alone.
Can I buy CJC-1295 no DAC for research?
Limitless Peptides sells CJC-1295 no DAC as a lyophilized powder in a sealed 3mL glass ampule. The product is Janoshik verified for identity, potency, and purity. CJC-1295 no DAC is sold for research use only and is not approved for human consumption. The product page includes the manufacturer's certificate of analysis and a link to the independent Janoshik verification report.
